Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 3, 2007, Pages 1085-1088

  Zhou, Juyan ^a   Chen, Yunhua ^a   Tabibi, Setareh ^a   Alba, Luis ^a   Garber, Elizabeth ^a   Saiman, Lisa ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; CEFEPIME; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; IMIPENEM; MEROPENEM; MINOCYCLINE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BURKHOLDERIA CEPACIA; CYSTIC FIBROSIS; DRUG MEGADOSE; DRUG POTENTIATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BURKHOLDERIA CEPACIA COMPLEX; BURKHOLDERIA INFECTIONS; CYSTIC FIBROSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 33847674947     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00954-06     Document Type: Article

References (42)

1. Aaron, S. D., W. Ferris, D. A. Henry, D. P. Speert, and N. E. MacDonald. 2000. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am. J. Respir. Crit. Care Med. 161:1206-1212.
2. Aaron, S. D., K. L. Vandemheen, W. Ferris, D. Fergusson, E. Tullis, D. Haase, Y. Berthiaume, N. Brown, P. Wilcox, V. Yozghatlian, P. Bye, S. Bell, F. Chan, B. Rose, A. Jeanneret, A. Stephenson, M. Noseworthy, A. Freitag, N. Paterson, S. Doucette, C. Harbour, M. Ruel, and N. MacDonald. 2005. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 366:463-471.
3. Bevivino, A., C. Dalmastri, S. Tabacchioni, L. Chiarini, M. L. Belli, S. Piana, A. Materazzo, P. Vandamme, and G. Manno. 2002. Burkholderia cepacia complex bacteria from clinical and environmental sources in Italy: genomovar status and distribution of traits related to virulence and transmissibility. J. Clin. Microbiol. 40:846-851.
4. Blumer, J. L., L. Saiman, M. W. Konstan, and D. Melnick. 2005. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 128:2336-2346.
5. Burns, J. L., and L. Saiman. 1999. Burkholderia cepacia infections in cystic fibrosis. Pediatr. Infect. Dis. J. 18:155-156.
6. Burns, J. L., C. D. Wadsworth, J. J. Barry, and C. P. Goodall. 1996. Nucleotide sequence analysis of a gene from Burkholderia (Pseudomonas) cepacia encoding an outer membrane lipoprotein involved in multiple antibiotic resistance. Antimicrob Agents Chemother. 40:307-313.
7. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing; 15th informational supplement, vol. 25. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing; 16th informational supplement, vol. 26. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Corey, M., and V. Farewell. 1996. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am. J. Epidemiol. 143:1007-1017.
10. Cystic Fibrosis Foundation. 1997. Patient registry 1996 annual report. Cystic Fibrosis Foundation, Bethesda, MD.
11. Cystic Fibrosis Foundation. 1998. Patient registry 1997 annual report. Cystic Fibrosis Foundation, Bethesda, MD.
12. Cystic Fibrosis Foundation. 1999. Patient registry 1998 annual report. Cystic Fibrosis Foundation, Bethesda, MD.
13. Cystic Fibrosis Foundation. 2000. Patient registry 1999 annual report. Cystic Fibrosis Foundation, Bethesda, MD.
14. Cystic Fibrosis Foundation. 2001. Patient registry 2000 annual report. Cystic Fibrosis Foundation, Bethesda, MD.
15. Cystic Fibrosis Foundation. 2002. Patient registry 2001 annual report. Cystic Fibrosis Foundation, Bethesda, MD.
16. Cystic Fibrosis Foundation. 2003. Patient registry 2002 annual report. Cystic Fibrosis Foundation, Bethesda, MD.
17. Cystic Fibrosis Foundation. 2004. Patient registry 2003 annual report. Cystic Fibrosis Foundation, Bethesda, MD.
18. Cystic Fibrosis Foundation. 2005. Patient registry 2004 annual report. Cystic Fibrosis Foundation, Bethesda, MD.
19. Eliopoulos, G. M., and R. C. Moellering. 1991. Antibiotic combinations, p. 432-492. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. Williams & Wilkins Co., Baltimore, MD.
20. Gibson, R. L., J. L. Burns, and B. W. Ramsey. 2003. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168:918-951.
21. Gilbert, D., R. Moellering, G. Eliopoulos, and M. Sande (ed.). 2005. The Sanford Guide to Antimicrobial Therapy, 35th ed. Antimicrobial Therapy, Inc., Hyde Park, VT.
22. Govan, J. R., and V. Deretic. 1996. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol. Rev. 60:539-574.
23. Hancock, R. E. 1998. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin. Infect. Dis. 27(Suppl. 1): S93-S99.
24. Isles, A., I. Maclusky, M. Corey, R. Gold, C. Prober, P. Fleming, and H. Levison. 1984. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J. Pediatr. 104:206-210.
25. Jacobs, D. S., W. R. DeMott, and D. K. Oxley. 2001. Jacobs & DeMott laboratory test handbook: with key word index, 5th ed. Lexi Comp, Hudson, OH.
26. Liou, T. G., F. R. Adler, S. C. Fitzsimmons, B. C. Cahill, J. R. Hibbs, and B. C. Marshall. 2001. Predictive 5-year survivorship model of cystic fibrosis. Am. J. Epidemiol. 153:345-352.
27. Mandell, G. L., J. E. Bennett, and R. Dolin. 2005. Principles and practice of infectious diseases, 6th ed. Elsevier Inc., Philadelphia, PA.
28. McMenamin, J. D., T. M. Zaccone, T. Coenye, P. Vandamme, and J. J. LiPuma. 2000. Misidentification of Burkholderia cepacia in US cystic fibrosis treatment centers: an analysis of 1,051 recent sputum isolates. Chest 117:1661-1665.
29. Moss, R. B. 1995. Cystic fibrosis: pathogenesis, pulmonary infection, and treatment. Clin. Infect. Dis. 21:839-849.
30. Nair, B. M., K. J. Cheung, Jr., A. Griffith, and J. L. Burns. 2004. Salicylate induces an antibiotic efflux pump in Burkholderia cepacia complex genomovar III (B. cenocepacia). J. Clin. Investig. 113:464-473.
31. Navarro, J., M. Rainisio, H. K. Harms, M. E. Hodson, C. Koch, G. Mastella, B. Strandvik, and S. G. McKenzie. 2001. Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European Epidemiologic Registry of Cystic Fibrosis. Eur. Respir. J. 18:298-305.
32. NCCLS. 2001. Performance standards for antimicrobial susceptibility testing; 11th informational supplement, vol. 21, M100-S11. NCCLS, Wayne, PA.
33. Nzula, S., P. Vandamme, and J. R. Govan. 2002. Influence of taxonomic status on the in vitro antimicrobial susceptibility of the Burkholderia cepacia complex. J. Antimicrob Chemother. 50:265-269.
34. Odds, F. C. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1.
35. Ramsey, B. W. 1996. Management of pulmonary disease in patients with cystic fibrosis. N. Engl. J. Med. 335:179-188.
36. Saiman, L., Y. Chen, S. Tabibi, P. San Gabriel, J. Zhou, Z. Liu, L. Lai, and S. Whittier. 2001. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J. Clin. Microbiol. 39:3942-3945.
37. Saiman, L., F. Mehar, W. W. Niu, H. C. Neu, K. J. Shaw, G. Miller, and A. Prince. 1996. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin. Infect. Dis. 23:532-537.
38. Saiman, L., and J. Siegel. 2003. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect. Control Hosp. Epidemiol. 24:S6-S52.
39. San Gabriel, P., J. Zhou, S. Tabibi, Y. Chen, M. Trauzzi, and L. Saiman. 2004. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 48:168-171.
40. Tablan, O. C., W. J. Martone, C. F. Doershuk, R. C. Stern, M. J. Thomassen, J. D. Klinger, J. W. White, L. A. Carson, and W. R. Jarvis. 1987. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes. Chest 91:527-532.
41. Taylor, R. F., H. Gaya, and M. E. Hodson. 1993. Pseudomonas cepacia: pulmonary infection in patients with cystic fibrosis. Respir. Med. 87:187-192.
42. Vermis, K., P. A. Vandamme, and H. J. Nelis. 2003. Burkholderia cepacia complex genomovars: utilization of carbon sources, susceptibility to antimicrobial agents and growth on selective media. J. Appl. Microbiol. 95:1191-1199.